medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 2

<< Back Next >>

Ann Hepatol 2013; 12 (2)

Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice

Miquel M, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, Canós AP

Language: English
References: 31
Page: 205-212
PDF size: 121.82 Kb.


ABSTRACT

This study aimed to evaluate the efficacy and safety of entecavir and/or tenofovir in compensated (CC) or decompensated (DC) hepatitis B cirrhotic patients in real-life clinical practice. Of the 48 patients, included between April 2007 and March 2010, 12 were DC. The mean age was 55 ± 12.2 years, 85.4% were Caucasians and 8 patients were HBeAg positive. Mean viral load was 5.2 ± 1.9 log10 UI/mL. HBV-DNA undetectability at 3, 6, 12 and 24 months were 53.3%, 78.3%, 83.7% and 97.1%, respectively, similar in CC and DC. At 6 and 12 months, ≥ 80% of CC achieved ALT normalization, while only 42.9% and 71.4% in DC. After a median follow-up of 27.1 (0.7-45.3) months, 43 patients were Child Pugh Turcotte (CPT) class A (n = 39 at entry). In DC, progressive improvement in the MELD scores was observed: 12.73 (SD 4.5), 10.4 (SD 3.6) and 8.2 (SD 2.6), at baseline, 12 and 24 months, respectively. During follow-up, 7 patients died, 4 received liver transplantation and 5 developed hepatocellular carcinoma. In three out of four DC who died due to hepatic causes, these events occurred between the first 0.7 and 6.7 months, and all were CPT class C. Cumulative survival in CC vs. DC at 12 and 24 months were 94.4% vs. 66.7%, and 88.2% vs. 57.1%, respectively (log rank p = 0.03). No severe adverse events associated with entecavir or tenofovir were reported. In conclusion, in compensated and decompensated cirrhotic patients, entecavir and tenofovir were effective and well tolerated.


REFERENCES

  1. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.

  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitis 2004; 11: 97-107.

  3. Liaw YF. Prevention and surveillance of hepatitis B virusrelated hepatocellular carcinoma. Semin Liver Dis 2005; 25: 40-7.

  4. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.

  5. Alter MJ. Epidemiology and prevention of Hepatitis B. Semin Liver Dis 2003; 23: 39-46.

  6. Berg T, Benhamou Y, Calleja JL, Levrero M, JohnsonW, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepatitis 2010; 17: 624-30.

  7. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, et al. Long-Term Entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.

  8. Schiff ER, Lee SS, Chao YC, Yoon SK, Bessone F, Wu SS, Kryczka W, et al. Long-term treatment with Entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastro Hepatol 2011; 9: 274-6.

  9. Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington M, Barnes CN, et al. Five years of treatment with Tenofovir DF (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54(Suppl. 1): A1429.

  10. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.

  11. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, et al., for the Chronic Hepatitis B Guideline Workshop Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.

  12. Fontana RJ. Entecavir in decompensated HBV cirrhosis: The future is looking brighter. J Hepatol 2010; 52: 147-9.

  13. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  14. Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.

  15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  16. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus related cirrhosis. Liver Transpl 2003; 9: 49-56.

  17. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, et al. Adefovir dipivoxil for wait-listed and post-liver transplantationpatients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.

  18. Gane EJ, Chan HL, Choudhuri G, Suh DJ, Chutaputti A, Safadi R, Tanwandee T, et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52(Suppl. 1): S4.

  19. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.

  20. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-12.

  21. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.

  22. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-6.

  23. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.

  24. Shim JH, Lee HC, Ki KM, Kim Y-S, Chung Y-H, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve decompensated cirrhosis. J Hepatol 2010; 52: 176-82.

  25. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, openlabel study. Hepatology 2011; 54: 91-100.

  26. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012; 32: 656-64.

  27. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Wong FS-H, Chang TT, et al. Tenofovir disoproxil fumarate (TDF), Emtricitabine/TDF, and Entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.

  28. D’Amico G, Gasrcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

  29. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.

  30. Fontana RJ, Hann H-WL, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.

  31. Lange CM, Bojunga J, Hoffmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazi C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-9.




2020     |     www.medigraphic.com